Pipeline
REGENXBIO shares 2-year data on gene therapy injection for wet AMD
Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.Research
Study links pandemic-induced psychosocial functions to visual impairment
Vision impairment could be a potential risk factor for psychosocial dysfunction and social isolation.Legal
Florida ODs kill yet another not-a-doctor bill
Just 9 months after the governor’s veto of S.B. 230, legislators failed to continue the state’s ongoing ‘eyeball wars.’Research
Foundation Fighting Blindness partners with BlueRock Therapeutics on IRD study
Collaboration will add a new cohort to the nonprofit’s Uni-Rare natural history study.Research
EHR-based reminders may bring back no-show patients
Clinical trial investigates the relationship between electronic reminders and patient re-engagement.Events
Eye safety tips you need to know ahead of the solar eclipse
Leading eyecare organizations and clinical experts offer their professional advice for safely watching this year’s big event on April 8.Products
Astellas receives permanent J-code for IZERVAY
FDA-approved therapy is the first and only GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint.Pipeline
Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP
Statistical significance noted for MCO-010 in demonstrating clinically meaningful vision improvement for legally blind, advanced RP patients.Research
Is lotilaner for Demodex effective at 1 year?
Saturn-1 extension study compares continued safety and efficacy of lotilaner after both 6 and 12 monthsProducts
Viatris Eye Care Division launches new YouTube channel aimed at fostering dialogue between dry eye patients and ECPs
A new YouTube channel is making it easier for eyecare professionals and patients to talk about dry eye disease.Business
Lenz Therapeutics merges with Graphite Bio
Combined company under LENZ is focusing on advancing two presbyopia therapeutic candidates.Research
iStent inject with cataract surgery may reduce glaucoma meds
iStent Inject demonstrates clinically and statistically significant reduction in glaucoma medications at 2 years.Pipeline
Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint
Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.Research
Study finds Nanodropper Adaptor demonstrates efficacy and safety as glaucoma treatment
Non-inferiority study evaluates microdrops vs conventional eye drops for lowering IOP.Research
University of Purdue receives $6.7M grant to advance development of smart contacts
Soft contact lenses are designed to provide continuous, 24/7 monitoring of IOP for glaucoma.Legal
AAO weighs in on Congress passing Medicare Physician Payment adjustment
Partial funding bill softens the original conversion factor decrease of 3.37% that took effect on Jan. 1, 2024.Research
Researchers tie DR to cardiovascular disease
New study suggests DR and CVD could potentially act as independent markers of each other.Business
Clearside Biomedical names retinal industry veteran as CMO
Victor Chong, MD, MBA, assumed his new role on March 14.Pipeline
GenSight Biologics reports 4-year efficacy and safety data on LUMEVOQ for LHON
Latest results confirm 3-year safety and efficacy of one-time injection in unilateral- and bilateral-treated eyes.Research